References
- Akram, M., Tahir, I. M., Shah, S. M. A., Mahmood, Z., Altaf, A., Ahmad, K., Munir, N., Daniyal, M., Nasir, S. and Mehboob, H. (2018). Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: A systematic review. Phytotherapy Research, 32(5), 811–822. https://doi.org/https://doi.org/10.1002/ptr.6024
- Ashburn, T. T., & Thor, K. B. (2004). Drug repositioning: Identifying and developing new uses for existing drugs. Nature Reviews. Drug Discovery, 3(8), 673–683. https://doi.org/https://doi.org/10.1038/nrd1468
- Ashraf, M. U., Iman, K., Khalid, M. F., Salman, H. M., Shafi, T., Rafi, M., Javaid, N., Hussain, R., Ahmad, F., Shahzad-Ul-Hussan, S., Mirza, S., Shafiq, M., Afzal, S., Hamera, S., Anwar, S., Qazi, R., Idrees, M., Qureshi, S. A., & Chaudhary, S. U. (2019). Evolution of efficacious pangenotypic hepatitis C virus therapies. Medicinal Research Reviews, 39(3), 1091–1136. https://doi.org/https://doi.org/10.1002/med.21554
- Astuti, I. & Ysrafil. (2020). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetology & Metabolic Syndrome, 14(4), 407–412. https://doi.org/https://doi.org/10.1016/j.dsx.2020.04.020
- Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., & Bourne, P. E. (2000). The Protein Data Bank. Nucleic Acids Research, 28(1), 235–242. https://doi.org/https://doi.org/10.1093/nar/28.1.235
- Bhardwaj, K., Sun, J., Holzenburg, A., Guarino, L. A., & Kao, C. C. (2006). RNA recognition and cleavage by the SARS coronavirus endoribonuclease. Journal of Molecular Biology, 361(2), 243–256. https://doi.org/https://doi.org/10.1016/j.jmb.2006.06.021
- Bisson, J., McAlpine, J. B., Friesen, J. B., Chen, S. N., Graham, J., & Pauli, G. F. (2016). Can invalid bioactives undermine natural product-based drug discovery? Journal of Medicinal Chemistry, 59(5), 1671–1690. https://doi.org/https://doi.org/10.1021/acs.jmedchem.5b01009
- Bosseboeuf, E., Aubry, M., Nhan, T., de Pina, J. J., Rolain, J. M., & Raoult, D. (2018). Azithromycin inhibits the replication of Zika virus. J Antivirals Antiretrovirals, 10(1), 6–11. https://doi.org/https://doi.org/10.4172/1948-5964.1000173
- Bouvet, M., Debarnot, C., Imbert, I., Selisko, B., Snijder, E. J., Canard, B., & Decroly, E. (2010). In vitro reconstitution of SARS-coronavirus mRNA cap methylation. PLoS Pathogens, 6(4), e1000863. https://doi.org/https://doi.org/10.1371/annotation/a0dde376-2eb1-4ce3-8887-d29f5ba6f162
- Brimacombe, K. R., et al. (2020). An OpenData portal to share COVID-19 drug repurposing data in real time. bioRxiv, p. 2020.06.04.135046. https://doi.org/https://doi.org/10.1101/2020.06.04.135046
- Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 178, 104787. https://doi.org/https://doi.org/10.1016/j.antiviral.2020.104787
- Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C., Di, N. R. (2020). Features, evaluation and treatment coronavirus (COVID-19). StatPearls, StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK554776/
- Cavalla, D., Oerton, E., & Bender, A. (2017). 1.02 – Drug repurposing review. In Chackalamannil, S., Rotella, D. P., Ward, S. E. (Eds.), Reference module in chemistry, molecular sciences and chemical engineering (pp. 11–47). Elsevier. https://doi.org/https://doi.org/10.1016/B978-0-12-409547-2.12283-8
- Chen, Y., Liu, Q., & Guo, D. (2020). Emerging coronaviruses: Genome structure, replication, and pathogenesis. Journal of Medical Virology, 92(4), 418–423. https://doi.org/https://doi.org/10.1002/jmv.25681
- Chen, Y., Su, C., Ke, M., Jin, X., Xu, L., Zhang, Z., Wu, A., Sun, Y., Yang, Z., Tien, P., Ahola, T., Liang, Y., Liu, X., & Guo, D. (2011). Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribose 2'-O-methylation by nsp16/nsp10 protein complex. PLoS Pathogens, 7(10), e1002294. https://doi.org/https://doi.org/10.1371/journal.ppat.1002294
- Clark, A., Jit, M., Warren-Gash, C., Guthrie, B., Wang, H. H. X., Mercer, S. W., Sanderson, C., McKee, M., Troeger, C., Ong, K. L., Checchi, F., Perel, P., Joseph, S., Gibbs, H. P., Banerjee, A., Eggo, R. M., Nightingale, E. S., O'Reilly, K., Jombart, T., … Jarvis, C. I. (2020). Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: A modelling study. The Lancet Global Health, 8(8), e1003–e1017. https://doi.org/https://doi.org/10.1016/S2214-109X(20)30264-3
- Colson, P., & Raoult, D. (2016). Fighting viruses with antibiotics: An overlooked path. International Journal of Antimicrobial Agents, 48(4), 349–352. https://doi.org/https://doi.org/10.1016/j.ijantimicag.2016.07.004
- Deng, X., & Baker, S. C. (2018). An “Old” protein with a new story: Coronavirus endoribonuclease is important for evading host antiviral defenses. Virology, 517, 157–163. https://doi.org/https://doi.org/10.1016/j.virol.2017.12.024
- Ellinger, B., et al. (2020). Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection. Research Square. https://doi.org/https://doi.org/10.21203/RS.3.RS-23951/V1
- Fehr, A. R., & Perlman, S. (2015). Coronaviruses: An overview of their replication and pathogenesis. Methods in Molecular Biology, 1282, 1–23. doi: https://doi.org/10.1007/978-1-4939-2438-7_1
- Ganeshpurkar, A., & Saluja, A. K. (2017). The pharmacological potential of rutin. Saudi Pharmaceutical Journal, 25(2), 149–164. https://doi.org/https://doi.org/10.1016/j.jsps.2016.04.025
- Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Tissot Dupont, H., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J.-M., Brouqui, P., & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 56(1), 105949. doi: https://doi.org/10.1016/j.ijantimicag.105949
- Ge, Y., et al. (2020). A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. bioRxiv, p. 2020.03.11.986836. https://doi.org/https://doi.org/10.1101/2020.03.11.986836
- Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O'Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., Tummino, T. A., Hüttenhain, R., Kaake, R. M., Richards, A. L., Tutuncuoglu, B., Foussard, H., Batra, J., Haas, K., Modak, M., … Krogan, N. J. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 583(7816), 459–468. https://doi.org/https://doi.org/10.1038/s41586-020-2286-9
- Hackbart, M., Deng, X., & Baker, S. C. (2020). Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors. Proceedings of the National Academy of Sciences of the United States of America, 117(14), 8094–8103. https://doi.org/https://doi.org/10.1073/pnas.1921485117
- Hawkins, P. C. D., Skillman, A. G., Warren, G. L., Ellingson, B. A., & Stahl, M. T. (2010). Conformer generation with OMEGA: Algorithm and validation using high quality structures from the protein databank and Cambridge structural database. Journal of Chemical Information and Modeling, 50(4), 572–584. https://doi.org/https://doi.org/10.1021/ci100031x
- Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181(2), 271–280.e8. https://doi.org/https://doi.org/10.1016/j.cell.2020.02.052
- Hsieh, P. K., Chang, S. C., Huang, C. C., Lee, T. T., Hsiao, C. W., Kou, Y. H., Chen, I. Y., Chang, C. K., Huang, T. H., & Chang, M. F. (2005). Assembly of severe acute respiratory syndrome coronavirus RNA packaging signal into virus-like particles is nucleocapsid dependent. Journal of Virology, 79(22), 13848–13855. https://doi.org/https://doi.org/10.1128/JVI.79.22.13848-13855.2005
- Ispas, G., Koul, A., Verbeeck, J., Sheehan, J., Sanders-Beer, B., Roymans, D., Andries, K., Rouan, M. C., De Jonghe, S., Bonfanti, J. F., Vanstockem, M., Simmen, K., & Verloes, R. (2015). Antiviral activity of TMC353121, a respiratory syncytial virus (RSV) fusion inhibitor, in a non-human primate model. PLoS One, 10(5), e0126959https://doi.org/https://doi.org/10.1371/journal.pone.0126959
- Ivashchenko, A. A., Dmitriev, K. A., Vostokova, N. V., Azarova, V. N., Blinow, A. A., Egorova, A. N., Gordeev, I. G., Ilin, A. P., Karapetian, R. N., Kravchenko, D. V., Lomakin, N. V., Merkulova, E. A., Papazova, N. A., Pavlikova, E. P., Savchuk, N. P., Simakina, E. N., Sitdekov, T. A., Smolyarchuk, E. A., Tikhomolova, E. G., Yakubova, E. V., & Ivachtchenko, A. V. (2020). AVIFAVIR for treatment of patients with moderate COVID-19: Interim results of a phase II/III multicenter randomized clinical trial. Clinical Infectious Diseases. https://doi.org/https://doi.org/10.1093/cid/ciaa1176
- Jiménez-Alberto, A., Ribas-Aparicio, R. M., Aparicio-Ozores, G., & Castelán-Vega, J. A. (2020). Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors. Computational Biology and Chemistry, 88, 107325. https://doi.org/https://doi.org/10.1016/j.compbiolchem.2020.107325
- Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., Duan, Y., Yu, J., Wang, L., Yang, K., Liu, F., Jiang, R., Yang, X., You, T., Liu, X., … Yang, H. (2020). Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature, 582(7811), 289–229. https://doi.org/https://doi.org/10.1038/s41586-020-2223-y
- Ke, M., Chen, Y., Wu, A., Sun, Y., Su, C., Wu, H., Jin, X., Tao, J., Wang, Y., Ma, X., Pan, J.-A., & Guo, D. (2012). Short peptides derived from the interaction domain of SARS coronavirus nonstructural protein nsp10 can suppress the 2'-O-methyltransferase activity of nsp10/nsp16 complex. Virus Research, 167(2), 322–328. https://doi.org/https://doi.org/10.1016/j.virusres.2012.05.017
- Kesel, A. J., Huang, Z., Murray, M. G., Prichard, M. N., Caboni, L., Nevin, D. K., Fayne, D., Lloyd, D. G., Detorio, M. A., & Schinazi, R. F. (2014). Retinazone inhibits certain blood-borne human viruses including Ebola virus Zaire. Antiviral Chemistry & Chemotherapy, 23(5), 197–215. https://doi.org/https://doi.org/10.3851/IMP2568
- Kim, Y., et al. (2020). Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2. bioRxiv, p. 2020.06.26.173872. https://doi.org/https://doi.org/10.1101/2020.06.26.173872
- Kumar, V., & Jena, M. (2020). In silico virtual screening-based study of nutraceuticals predicts the therapeutic potentials of folic acid and its derivatives against COVID-19. PREPRINT (Version 1) Available at Research Square. https://doi.org/https://doi.org/10.21203/rs.3.rs-31775/v1
- Kumar, Y., Singh, H., & Patel, C. N. (2020). In silico prediction of potential inhibitors for the Main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Journal of Infection and Public Health, 13(9), 1210–1223. https://doi.org/https://doi.org/10.1016/j.jiph.2020.06.016
- Ladbury, J. E. (1996). Just add water! The effect of water on the specificity of protein- ligand binding sites and its potential application to drug design. Chemistry & Biology, 3(12), 973–980. https://doi.org/https://doi.org/10.1016/S1074-5521(96)90164-7
- Leach, A. R., Gillet, V. J., Lewis, R. A., & Taylor, R. (2010). Three-dimensional pharmacophore methods in drug discovery. Journal of Medicinal Chemistry, 53(2), 539–558. https://doi.org/https://doi.org/10.1021/jm900817u
- Lei, J., Kusov, Y., & Hilgenfeld, R. (2018). Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein. Antiviral Research, 149, 58–74. https://doi.org/https://doi.org/10.1016/j.antiviral.2017.11.001
- Li, G., & De Clercq, E. (2020). Therapeutic options for the 2019 novel coronavirus (2019-nCoV)). Nature Reviews. Drug Discovery, 19(3), 149–150. https://doi.org/https://doi.org/10.1038/d41573-020-00016-0
- Li, S. Y., Chen, C., Zhang, H. Q., Guo, H. Y., Wang, H., Wang, L., Zhang, X., Hua, S. N., Yu, J., Xiao, P. G., Li, R. S., & Tan, X. (2005). Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Research, 67(1), 18–23. https://doi.org/https://doi.org/10.1016/j.antiviral.2005.02.007
- Long, D., & Yang, D. (2009). Buffer interference with protein dynamics: A case study on human liver fatty acid binding protein. Biophysical Journal, 96(4), 1482–1488. https://doi.org/https://doi.org/10.1016/j.bpj.2008.10.049
- Madrid, P. B., Panchal, R. G., Warren, T. K., Shurtleff, A. C., Endsley, A. N., Green, C. E., Kolokoltsov, A., Davey, R., Manger, I. D., Gilfillan, L., Bavari, S., & Tanga, M. J. (2015). Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infectious Diseases, 1(7), 317–326. https://doi.org/https://doi.org/10.1021/acsinfecdis.5b00030
- Marra, M. A., Jones, S. J. M., Astell, C. R., Holt, R. A., Brooks-Wilson, A., Butterfield, Y. S. N., Khattra, J., Asano, J. K., Barber, S. A., Chan, S. Y., Cloutier, A., Coughlin, S. M., Freeman, D., Girn, N., Griffith, O. L., Leach, S. R., Mayo, M., McDonald, H., Montgomery, S. B., … Roper, R. L. (2003). The genome sequence of the SARS-associated coronavirus. Science, 300(5624), 1399–1404. https://doi.org/https://doi.org/10.1126/science.1085953
- Martin, W. R., & Cheng, F. (2020). Repurposing of FDA-approved toremifene to treat COVID-19 by blocking the spike glycoprotein and NSP14 of SARS-CoV-2. chemRxiv. https://doi.org/https://doi.org/10.26434/CHEMRXIV.12431966.V1
- Masters, P. S., & Sturman, L. S. (1990). Background paper. Functions of the coronavirus nucleocapsid protein. Advances in Experimental Medicine and Biology, 276, 235–238. https://doi.org/https://doi.org/10.1007/978-1-4684-5823-7_32
- Mawhinney, L., Armstrong, M. E., O’Reilly, C., Bucala, R., Leng, L., Fingerle-Rowson, G., Fayne, D., Keane, M. P., Tynan, A., Maher, L., Cooke, G., Lloyd, D., Conroy, H., & Donnelly, S. C. (2014). Macrophage migration inhibitory factor (MIF), enzymatic activity & lung cancer. Molecular Medicine, 20(1), 729–735. https://doi.org/https://doi.org/10.2119/molmed.2014.00136
- McBride, R., van Zyl, M., & Fielding, B. C. (2014). The coronavirus nucleocapsid is a multifunctional protein. Viruses, 6(8), 2991–3018. https://doi.org/https://doi.org/10.3390/v6082991
- McInnes, C. (2007). Virtual screening strategies in drug discovery. Current Opinion in Chemical Biology, 11(5), 494–502. https://doi.org/https://doi.org/10.1016/j.cbpa.2007.08.033
- McKay, P. B., Fayne, D., Horn, H. W., James, T., Peters, M. B., Carta, G., Caboni, L., Nevin, D. K., Price, T., Bradley, G., Williams, D. C., Rice, J. E., & Lloyd, D. G. (2012). Consensus computational ligand-based design for the identification of novel modulators of human Estrogen Receptor alpha. Molecular Informatics, 31(3-4), 246–258. https://doi.org/https://doi.org/10.1002/minf.201100127
- Menachery, V. D., Mitchell, H. D., Cockrell, A. S., Gralinski, L. E., Yount, B. L., Graham, R. L., McAnarney, E. T., Douglas, M. G., Scobey, T., Beall, A., Dinnon, K., Kocher, J. F., Hale, A. E., Stratton, K. G., Waters, K. M., & Baric, R. S. (2017). MERS-CoV accessory ORFs play key role for infection and pathogenesis. mBio, 8(4), e0066517. https://doi.org/https://doi.org/10.1128/mBio.00665-17
- Molecular Operating Environment (MOE). (2020). 2019.01; Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7.
- Mousavizadeh, L., & Ghasemi, S. (2020). Genotype and phenotype of COVID-19: Their roles in pathogenesis. Journal of Microbiology, Immunology and Infection. https://doi.org/https://doi.org/10.1016/j.jmii.2020.03.022
- Munster, V. J., Koopmans, M., van Doremalen, N., van Riel, D., & de Wit, E. (2020). A novel coronavirus emerging in China – Key questions for impact assessment. The New England Journal of Medicine, 382(8), 692–694. https://doi.org/https://doi.org/10.1056/NEJMp2000929
- Muthas, D., Sabnis, Y. A., Lundborg, M., & Karlen, A. (2008). Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering. Journal of Molecular Graphics & Modelling, 26(8), 1237–1251. https://doi.org/https://doi.org/10.1016/j.jmgm.2007.11.005
- Najmanovich, R., Kuttner, J., Sobolev, V., & Edelman, M. (2000). Side-chain flexibility in proteins upon ligand binding. Proteins: Structure, Function, and Genetics, 39(3), 261–268. https://doi.org/https://doi.org/10.1002/(SICI)1097-0134(20000515)39:3<261::AID-PROT90>3.0.CO;2-4
- Nevin, D. K., Peters, M. B., Carta, G., Fayne, D., & Lloyd, D. G. (2012). Integrated virtual screening for the identification of novel and selective Peroxisome proliferator-activated receptor (PPAR) scaffolds. Journal of Medicinal Chemistry, 55(11), 4978–4989. https://doi.org/https://doi.org/10.1021/jm300068n
- OMEGA. (2019). OMEGA 3.1.1.2: OpenEye Scientific Software. http://www.eyesopen.com
- O’Neill, L. A. J., & Netea, M. G. (2020). BCG-induced trained immunity: Can it offer protection against COVID-19? Nature Reviews. Immunology, 20(6), 335–337. https://doi.org/https://doi.org/10.1038/s41577-020-0337-y
- Pacios, O., Blasco, L., Bleriot, I., Fernandez-Garcia, L., González Bardanca, M., Ambroa, A., López, M., Bou, G., & Tomás, M. (2020). Strategies to combat multidrug-resistant and persistent infectious diseases. Antibiotics, 9(2), 65. https://doi.org/https://doi.org/10.3390/antibiotics9020065
- Pan, J., Peng, X., Gao, Y., Li, Z., Lu, X., Chen, Y., Ishaq, M., Liu, D., Dediego, M. L., Enjuanes, L., & Guo, D. (2008). Genome-wide analysis of protein-protein interactions and involvement of viral proteins in SARS-CoV replication. PLoS One, 3(10), e3299. https://doi.org/https://doi.org/10.1371/journal.pone.0003299
- Pandey, A., Nikam, A. N., Shreya, A. B., Mutalik, S. P., Gopalan, D., Kulkarni, S., Padya, B. S., Fernandes, G., Mutalik, S., & Prassl, R. (2020). Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. Life Sciences, 256, 117883. https://doi.org/https://doi.org/10.1016/j.lfs.2020.117883
- Pant, S., Singh, M., Ravichandiran, V., Murty, U., & Srivastava, H. K. (2020). Peptide-like and small-molecule inhibitors against Covid-19. Journal of Biomolecular Structure and Dynamics. https://doi.org/https://doi.org/10.1080/07391102.2020.1757510
- Pár, A., & Pár, G. (2018). [Three decades of the hepatitis C virus from the discovery to the potential global elimination: The success of translational researches]. Orvosi Hetilap, 159(12), 455–465. https://doi.org/https://doi.org/10.1556/650.2018.30997
- Patskovsky, Y. V., Negrebetskaya, E. N., Chernomaz, A. A., Voloshchuk, T. P., Rubashevsky, E. L., Kitam, O. E., Tereshchenko, M. I., Nosach, L. N., & Potopalsky, A. I. (1996). Aromatic thiosemicarbazones, their antiviral action and interferon. 1. The decreasing of adenovirus type 1 resistance against interferon by methisazone in vitro. Biopolymers and Cell, 12(2), 74–83. https://doi.org/https://doi.org/10.7124/bc.000425
- Peele, K. A., Chandrasai, P., Srihansa, T., Krupanidhi, S., Sai, A. V., Babu, D. J., Indira, M., Reddy, A. R., & Venkateswarulu, T. C. (2020). Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study. Informatics in Medicine Unlocked, 19, 100345. https://doi.org/https://doi.org/10.1016/j.imu.2020.100345
- Perlman, S., & Netland, J. (2009). Coronaviruses post-SARS: Update on replication and pathogenesis. Nature Reviews Microbiology, 7(6), 439–450. https://doi.org/https://doi.org/10.1038/nrmicro2147
- Qadir, A., Riaz, M., Saeed, M., & Shahzad-Ul-Hussan, S. (2018). Potential targets for therapeutic intervention and structure based vaccine design against Zika virus. European Journal of Medicinal Chemistry, 156, 444–460. https://doi.org/https://doi.org/10.1016/j.ejmech.2018.07.014
- Sanders, M. P. A., McGuire, R., Roumen, L., de Esch, I. J. P., de Vlieg, J., Klomp, J. P. G., & de Graaf, C. (2012). From the protein’s perspective: The benefits and challenges of protein structure-based pharmacophore modelling. MedChemComm, 3(1), 28–38. https://doi.org/https://doi.org/10.1039/C1MD00210D
- Santibáñez-Morán, M. G., López-López, E., Prieto-Martínez, F. D., Sánchez-Cruz, N., & Medina-Franco, J. L. (2020). Consensus virtual screening of dark chemical matter and food chemicals uncover potential inhibitors of SARS-CoV-2 main protease. Version 1. ChemRxiv. https://doi.org/https://doi.org/10.26434/chemrxiv.12420860.v1
- Schiebel, J., Gaspari, R., Wulsdorf, T., Ngo, K., Sohn, C., Schrader, T. E., Cavalli, A., Ostermann, A., Heine, A., & Klebe, G. (2018). Intriguing role of water in protein-ligand binding studied by neutron crystallography on trypsin complexes. Nature Communications, 9(1), 3559. https://doi.org/https://doi.org/10.1038/s41467-018-05769-2
- Schneider, G. (2018). Automating drug discovery. Nature Reviews Drug Discovery, 17(2), 97–113. https://doi.org/https://doi.org/10.1038/nrd.2017.232
- Schneider, P., & Schneider, G. (2018). Polypharmacological drug-target inference for chemogenomics. Molecular Informatics, 37 (9-10), e1800050. https://doi.org/https://doi.org/10.1002/minf.201800050
- Shah, B., Modi, P., & Sagar, S. R. (2020). In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. Life Sciences, 252, 117652. https://doi.org/https://doi.org/10.1016/j.lfs.2020.117652
- Snijder, E. J., Bredenbeek, P. J., Dobbe, J. C., Thiel, V., Ziebuhr, J., Poon, L. L. M., Guan, Y., Rozanov, M., Spaan, W. J. M., & Gorbalenya, A. E. (2003). Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-o from the coronavirus group 2 lineage. Journal of Molecular Biology, 331(5), 991–1004. https://doi.org/https://doi.org/10.1016/S0022-2836(03)00865-9
- Snijder, E. J., Decroly, E., & Ziebuhr, J. (2016). The nonstructural proteins directing coronavirus RNA synthesis and processing. Advances in Virus Research, 96, 59–126. https://doi.org/https://doi.org/10.1016/bs.aivir.2016.08.008
- Snijder, E. J., Limpens, R., de Wilde, A. H., de Jong, A., Zevenhoven-Dobbe, J. C., Maier, H. J., Faas, F., Koster, A. J., & Bárcena, M. (2020). A unifying structural and functional model of the coronavirus replication organelle: Tracking down RNA synthesis. PLoS biology, 18(6), e3000715. https://doi.org/https://doi.org/10.1371/journal.pbio.3000715
- Su, H., et al. (2020). Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in-vitro. bioRxiv, p. 2020.04.13.038687. https://doi.org/https://doi.org/10.1101/2020.04.13.038687
- Subissi, L., Posthuma, C. C., Collet, A., Zevenhoven-Dobbe, J. C., Gorbalenya, A. E., Decroly, E., Snijder, E. J., Canard, B., & Imbert, I. (2014). One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities. Proceedings of the National Academy of Sciences of the United States of America, 111(37), E3900. https://doi.org/https://doi.org/10.1073/pnas.1323705111
- Surjit, M., Liu, B., Chow, V. T., & Lal, S. K. (2006). The nucleocapsid protein of severe acute respiratory syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks S phase progression in mammalian cells. Journal of Biological Chemistry, 281(16), 10669–10681. https://doi.org/https://doi.org/10.1074/jbc.M509233200
- Talevi, A., & Bellera, C. L. (2020). Challenges and opportunities with drug repurposing: Finding strategies to find alternative uses of therapeutics. Expert Opinion on Drug Discovery, 15(4), 397–401. https://doi.org/https://doi.org/10.1080/17460441.2020.1704729
- Tazikeh-Lemeski, E., Moradi, S., Raoufi, R., Shahlaei, M., Janlou, M., & Zolghadri, S. (2020). Targeting SARS-COV-2 non-structural protein 16: A virtual drug repurposing study. Journal of Biomolecular Structure and Dynamics. https://doi.org/https://doi.org/10.1080/07391102.2020.1779133
- von Brunn, A., Teepe, C., Simpson, J. C., Pepperkok, R., Friedel, C. C., Zimmer, R., Roberts, R., Baric, R., & Haas, J. (2007). Analysis of intraviral protein-protein interactions of the SARS coronavirus ORFeome. PLoS One, 2(5), e459. https://doi.org/https://doi.org/10.1371/journal.pone.0000459
- Wagner, M. C. (2011). The therapeutic potential of adenosine triphosphate as an immune modulator in the treatment of HIV/AIDS: A combination approach with HAART. Current HIV Research, 9(4), 209–222. https://doi.org/https://doi.org/10.2174/157016211796320289
- Walters, W. P., Stahl, M. T., & Murcko, M. A. (1998). Virtual screening – An overview. Drug Discovery Today, 3(4), 160–178. https://doi.org/https://doi.org/10.1016/S1359-6446(97)01163-X
- WHO. (2020). WHO Director-General's statement on IHR Emergency Committee on Novel Coronavirus (2019-nCoV). Accessed 15 July 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov)
- Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., Li, X., Zheng, M., Chen, L., & Li, H. (2020). Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B, 10(5), 766–788. https://doi.org/https://doi.org/10.1016/j.apsb.2020.02.008
- Xiong, H.-L., et al. (2020). Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro. bioRxiv. https://doi.org/https://doi.org/10.1101/2020.06.05.135996
- Yamaguchi, K., Honda, M., Ikigai, H., Hara, Y., & Shimamura, T. (2002). Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Research, 53(1), 19–34. https://doi.org/https://doi.org/10.1016/S0166-3542(01)00189-9
- Zhou, N., Pan, T., Zhang, J., Li, Q., Zhang, X., Bai, C., Huang, F., Peng, T., Zhang, J., Liu, C., Tao, L., & Zhang, H. (2016). Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). The Journal of Biological Chemistry, 291(17), 9218–9232. https://doi.org/https://doi.org/10.1074/jbc.M116.716100
- Ziebuhr, J. (2005). The coronavirus replicase. Current Topics in Microbiology and Immunology, 287, 57–94. https://doi.org/https://doi.org/10.1007/3-540-26765-4_3